We are Sorry, This Page doesn't Exist

Shares of Biogen Inc. gained 5.6% in trading on Monday after another drugmaker shared positive clinical data about an experimental Alzheimer's disease treatment that is similar to a Biogen therapy under review by the Food and Drug A.....»»

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Despite the controversy surrounding Biogen Inc's (NASDAQ: BIIB).....»»

Following Biogen Inc's (NASDAQ: BIIB) presentation of detailed top-line results for aducanumab at the Alzheimer's conference, the stock ended Thursday Latest Ratings for BIIB DateFirmAc.....»»

Analysts who parsed through it, said the lack of any new negatives in the report means that they expect the company will take the data to the Food and Drug Administration......»»

Shares of Biogen are up 3% after it released additional data about its recently resurrected Alzheimer's disease drug candidate. A fresh take on data from .....»»

Shares of Biogen fell 3% after it released additional data about its recently resurrected Alzheimer's disease drug candidate. A fresh take on data from .....»»

Biogen Inc (NASDAQ: BIIB) shares gained more than 25% earlier this year when the company said it planned a regulatory filing for its Alzheimer's drug aducanumab fo Latest Ratings for BIIB DateFirmAc.....»»

But an individual who claims to be a former R&D employee thinks the company may be ‘spinning’ the dataRelated Stocks: BIIB, TSE:4523, LLY,.....»»

Biogen Inc revived plans on Tuesday to seek U.S. approval for Alzheimer's treatment aducanumab, surprising investors and saying data from more patients in two discontinued studies showed the drug reduced the decline of patients......»»

Biogen resurrects Alzheimer"s drug; shares jump 27%.....»»

Shares of Biogen skyrocketed roughly 40 percent Tuesday after the biotech company said it will now seek approval for an Alzheimer's drug after abandoning the drug earlier this year......»»

Shares of Biogen skyrocketed roughly 40 percent Tuesday after the biotech company said it will seek approval for an Alzheimer's treatment after abandoning the drug earlier this year. Freddie Joyner has the story......»»

An experimental treatment for Alzheimer's disease declared a failure in March has been brought back to life......»»

Biogen on Tuesday made a surprising reversal on its Alzheimer's treatment with plans now to seek U.S. regulatory approval after data from more patients in two discontinued studies showed that the drug improved cognition at high doses......»»

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Biogen Inc (NASDAQ: BIIB) share.....»»

In reversal, Biogen to file for approval of Alzheimer"s drug.....»»

Biogen Inc (NASDAQ: BIIB) shares, which suffered a severe setback in early 2019 after the company's Alzheimer's program flopped, were seeing a resurgence Tuesday.  read more.....»»

The following is a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks that hit 52-week highs Oct. 21.) Aprea Therapeutics Inc.....»»